Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma

Seung Hyun Kim, Kyoo Ho Shin, seonghwan moon, Jinyoung Jang, Hyo Song Kim, Jinsuck Suh, Woo Ick Yang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The goal of this study was to reassess serum alkaline phosphatase (ALP) as tumor marker in osteosarcoma. We retrospectively examined serum ALP levels at diagnosis, every therapeutic step (neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy), metastasis, and follow-up and analyzed the role of ALP as tumor marker in 210 osteosarcomas. The diagnostic performances of ALP were validated with pathology-proven 899 other primary bone lesions. Elevated ALP at diagnosis was associated with inferior overall survival (OS) (Log Rank P < 0.001) and disease-free survival (Log Rank P = 0.005) and independently significant for OS in multivariate analysis (hazard ratio [HR]=2.12, P = 0.032). During therapy, the ALP level significantly changed according to therapeutic steps (P < 0.001 for patients ≥15 years old, P < 0.001 for patients <15 years old) and survival (P = 0.015 for ≥15 years, P = 0.002 for <15 years), and the response of ALP to therapy and survival were associated (P = 0.042 for ≥15 years, P = 0.036 for <15 years). Initial ALP level was linearly correlated with tumor burden (total tumor volume; P = 0.016 for ≥15 years, bone tumor volume; P = 0.012 for ≥15 years). The sensitivity and specificity of ALP on diagnosis were 53.2% (95% Confidence Interval [CI]: 0.475–0.586) and 90.1% (95% CI: 0.888–0.913). The sensitivity of ALP on metastasis was 53.2% (95% CI: 0.431–0.624), and the specificity was 78.2% (95% CI: 0.720–0.839) at15 months postoperative and 90.0% (95% CI: 0.824–0.952) at 3 years postoperative. Serum ALP was found to be a valuable tumor marker with high specificity in osteosarcoma.

Original languageEnglish
Pages (from-to)1311-1322
Number of pages12
JournalCancer medicine
Volume6
Issue number6
DOIs
Publication statusPublished - 2017 Jun 1

Fingerprint

Osteosarcoma
Tumor Biomarkers
Alkaline Phosphatase
Biomarkers
Confidence Intervals
Tumor Burden
Survival
Serum
Neoplasm Metastasis
Bone and Bones
Therapeutics
Adjuvant Chemotherapy
Disease-Free Survival
Multivariate Analysis
Pathology
Drug Therapy
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Kim, Seung Hyun ; Shin, Kyoo Ho ; moon, seonghwan ; Jang, Jinyoung ; Kim, Hyo Song ; Suh, Jinsuck ; Yang, Woo Ick. / Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. In: Cancer medicine. 2017 ; Vol. 6, No. 6. pp. 1311-1322.
@article{97ad7234cdba44fd8d35cf6b5f8a33de,
title = "Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma",
abstract = "The goal of this study was to reassess serum alkaline phosphatase (ALP) as tumor marker in osteosarcoma. We retrospectively examined serum ALP levels at diagnosis, every therapeutic step (neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy), metastasis, and follow-up and analyzed the role of ALP as tumor marker in 210 osteosarcomas. The diagnostic performances of ALP were validated with pathology-proven 899 other primary bone lesions. Elevated ALP at diagnosis was associated with inferior overall survival (OS) (Log Rank P < 0.001) and disease-free survival (Log Rank P = 0.005) and independently significant for OS in multivariate analysis (hazard ratio [HR]=2.12, P = 0.032). During therapy, the ALP level significantly changed according to therapeutic steps (P < 0.001 for patients ≥15 years old, P < 0.001 for patients <15 years old) and survival (P = 0.015 for ≥15 years, P = 0.002 for <15 years), and the response of ALP to therapy and survival were associated (P = 0.042 for ≥15 years, P = 0.036 for <15 years). Initial ALP level was linearly correlated with tumor burden (total tumor volume; P = 0.016 for ≥15 years, bone tumor volume; P = 0.012 for ≥15 years). The sensitivity and specificity of ALP on diagnosis were 53.2{\%} (95{\%} Confidence Interval [CI]: 0.475–0.586) and 90.1{\%} (95{\%} CI: 0.888–0.913). The sensitivity of ALP on metastasis was 53.2{\%} (95{\%} CI: 0.431–0.624), and the specificity was 78.2{\%} (95{\%} CI: 0.720–0.839) at15 months postoperative and 90.0{\%} (95{\%} CI: 0.824–0.952) at 3 years postoperative. Serum ALP was found to be a valuable tumor marker with high specificity in osteosarcoma.",
author = "Kim, {Seung Hyun} and Shin, {Kyoo Ho} and seonghwan moon and Jinyoung Jang and Kim, {Hyo Song} and Jinsuck Suh and Yang, {Woo Ick}",
year = "2017",
month = "6",
day = "1",
doi = "10.1002/cam4.1022",
language = "English",
volume = "6",
pages = "1311--1322",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. / Kim, Seung Hyun; Shin, Kyoo Ho; moon, seonghwan; Jang, Jinyoung; Kim, Hyo Song; Suh, Jinsuck; Yang, Woo Ick.

In: Cancer medicine, Vol. 6, No. 6, 01.06.2017, p. 1311-1322.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma

AU - Kim, Seung Hyun

AU - Shin, Kyoo Ho

AU - moon, seonghwan

AU - Jang, Jinyoung

AU - Kim, Hyo Song

AU - Suh, Jinsuck

AU - Yang, Woo Ick

PY - 2017/6/1

Y1 - 2017/6/1

N2 - The goal of this study was to reassess serum alkaline phosphatase (ALP) as tumor marker in osteosarcoma. We retrospectively examined serum ALP levels at diagnosis, every therapeutic step (neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy), metastasis, and follow-up and analyzed the role of ALP as tumor marker in 210 osteosarcomas. The diagnostic performances of ALP were validated with pathology-proven 899 other primary bone lesions. Elevated ALP at diagnosis was associated with inferior overall survival (OS) (Log Rank P < 0.001) and disease-free survival (Log Rank P = 0.005) and independently significant for OS in multivariate analysis (hazard ratio [HR]=2.12, P = 0.032). During therapy, the ALP level significantly changed according to therapeutic steps (P < 0.001 for patients ≥15 years old, P < 0.001 for patients <15 years old) and survival (P = 0.015 for ≥15 years, P = 0.002 for <15 years), and the response of ALP to therapy and survival were associated (P = 0.042 for ≥15 years, P = 0.036 for <15 years). Initial ALP level was linearly correlated with tumor burden (total tumor volume; P = 0.016 for ≥15 years, bone tumor volume; P = 0.012 for ≥15 years). The sensitivity and specificity of ALP on diagnosis were 53.2% (95% Confidence Interval [CI]: 0.475–0.586) and 90.1% (95% CI: 0.888–0.913). The sensitivity of ALP on metastasis was 53.2% (95% CI: 0.431–0.624), and the specificity was 78.2% (95% CI: 0.720–0.839) at15 months postoperative and 90.0% (95% CI: 0.824–0.952) at 3 years postoperative. Serum ALP was found to be a valuable tumor marker with high specificity in osteosarcoma.

AB - The goal of this study was to reassess serum alkaline phosphatase (ALP) as tumor marker in osteosarcoma. We retrospectively examined serum ALP levels at diagnosis, every therapeutic step (neoadjuvant chemotherapy, surgery, and adjuvant chemotherapy), metastasis, and follow-up and analyzed the role of ALP as tumor marker in 210 osteosarcomas. The diagnostic performances of ALP were validated with pathology-proven 899 other primary bone lesions. Elevated ALP at diagnosis was associated with inferior overall survival (OS) (Log Rank P < 0.001) and disease-free survival (Log Rank P = 0.005) and independently significant for OS in multivariate analysis (hazard ratio [HR]=2.12, P = 0.032). During therapy, the ALP level significantly changed according to therapeutic steps (P < 0.001 for patients ≥15 years old, P < 0.001 for patients <15 years old) and survival (P = 0.015 for ≥15 years, P = 0.002 for <15 years), and the response of ALP to therapy and survival were associated (P = 0.042 for ≥15 years, P = 0.036 for <15 years). Initial ALP level was linearly correlated with tumor burden (total tumor volume; P = 0.016 for ≥15 years, bone tumor volume; P = 0.012 for ≥15 years). The sensitivity and specificity of ALP on diagnosis were 53.2% (95% Confidence Interval [CI]: 0.475–0.586) and 90.1% (95% CI: 0.888–0.913). The sensitivity of ALP on metastasis was 53.2% (95% CI: 0.431–0.624), and the specificity was 78.2% (95% CI: 0.720–0.839) at15 months postoperative and 90.0% (95% CI: 0.824–0.952) at 3 years postoperative. Serum ALP was found to be a valuable tumor marker with high specificity in osteosarcoma.

UR - http://www.scopus.com/inward/record.url?scp=85018889546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018889546&partnerID=8YFLogxK

U2 - 10.1002/cam4.1022

DO - 10.1002/cam4.1022

M3 - Article

C2 - 28493412

AN - SCOPUS:85018889546

VL - 6

SP - 1311

EP - 1322

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

IS - 6

ER -